Koselugo (selumetinib) approved by FDA
KENILWORTH, N.J. —AstraZeneca and Merck announced that the U.S. Food and Drug Administration (FDA) has approved the kinase inhibitor Koselugo (selumetinib) for the treatment of pediatric patients two years of age and older with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas (PN). The FDA approval is based on positive results from the
